Comparative Pharmacology
Head-to-head clinical analysis: QINLOCK versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QINLOCK versus TEPMETKO.
QINLOCK vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
450 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor